|
|
|
|
|
Last Trade
|
Last Trade:
$153.74
|
Change:
-3.17 (-2.02%)
|
Trade Time:
02:39 PM EST
|
Market Cap:
$11.40B
|
|
|
|
|
|
|
Description of Business
|
|
We are a commercial-stage biopharmaceutical company focused on helping patients
through the discovery and development of unique RNA-targeted therapeutics, gene
therapy and other genetic therapeutic modalities for the treatment of rare
diseases. Applying our proprietary, highly-differentiated and innovative
technologies, and through collaborations with our strategic partners, we are
developing potential therapeutic candidates for a broad range of diseases and
disorders, including Duchenne muscular dystrophy ("DMD"), Limb-girdle muscular
dystrophies ("LGMDs"), Mucopolysaccharidosis type IIIA ("MPS IIIA") and Pompe.
Our first commercial product in the U.S., EXONDYS 51® (eteplirsen) Injection
("EXONDYS 51"), was granted accelerated approval by the FDA on September 19,
2016. EXONDYS 51 is indicated for the treatment of DMD in patients who have a
confirmed mutation of the DMD gene that is amenable to exon 51 skipping.
|
|
|
|